公开(公告)号：US20170035822A1

公开(公告)日：2017-02-09

申请号：US15304316

申请日：2015-04-17

Applicant: Korea Research Institute of Bioscience and Biotechnology

Inventor： Sei Ryang OH ,  Kyung Seop AHN ,  Seung Hyung KIM ,  In Sik SHIN ,  Hang JIN ,  Jung Hee KIM ,  Hyung Won RYU ,  Wan Yi LI ,  Sang Woo LEE ,  Joong Ku LEE ,  Sang Ho CHOI

IPC: A61K36/22 ,  A61K9/00 ,  A23L33/105 ,  A61K31/12

Abstract: The present invention relates to a composition for suppressing chronic obstructive pulmonary disease (COPD) comprising a Pistacia weinmannifolia extract, a fraction thereof, or a compound isolated therefrom and, more particularly, to a pharmaceutical composition for preventing or treating COPD comprising a Pistacia weinmannifolia extract, a fraction thereof, or a compound isolated therefrom; a food composition for preventing or improving COPD, and the compound isolated therefrom. The composition comprising a Pistacia weinmannifolia extract, a fraction thereof, or a compound isolated therefrom, according to the present invention, is not toxic, suppresses the invasion of inflammatory cells into the bronchial tube of a COPD-induced animal model, and effectively suppresses the expression of CXCL-1, TNF-α, or MIP-2. In addition, due to the use of a safety-proven herbal drug as a raw material, the composition of the present invention can resolve various side-effects of existing therapeutic agents for COPD, chronic obstructive bronchitis, chronic bronchiolitis, emphysema, multiple sclerosis, and acute and chronic inflammation, and thus can be effectively used as a composition for preventing, treating and remedying COPD.

Abstract translation: 本发明涉及一种抑制慢性阻塞性肺疾病（COPD）的组合物，其包含维斯特氏菌提取物，其分数或从其分离的化合物，更具体地，涉及用于预防或治疗COPD的药物组合物，所述药物组合物包含猕猴桃提取物（Pistacia weinmannifolia extract） ，其一部分，或从其分离的化合物; 用于预防或改善COPD的食物组合物和从其分离的化合物。 根据本发明的包含猕猴桃提取物，其馏分或从其分离的化合物的组合物是无毒的，抑制炎性细胞侵入COPD诱导的动物模型的支气管中，并有效地抑制 CXCL-1，TNF-α或MIP-2的表达。 此外，由于使用经安全验证的草药作为原料，本发明的组合物可以解决现有的COPD治疗剂，慢性阻塞性支气管炎，慢性细支气管炎，肺气肿，多发性硬化症， 和急性和慢性炎症，因此可以有效地用作预防，治疗和治疗COPD的组合物。